Valeant Makes Hostile $5.7B Bid for Cephalon
This article was originally published in The Pink Sheet Daily
Executive Summary
The offer, which Cephalon says its board will respond to during the week of April 4, comes as the company adjusts to life under new CEO J. Kevin Buchi.
You may also be interested in...
Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?
Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.
Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?
Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.
As Cephalon Rejects Valeant Bid, Valeant Officially Goes Hostile
Valeant's offer undervalues Cephalon, its assets and its prospects, and "ignores the proven ability" of its management to maximize opportunities, Cephalon's board says.